Drugs Habits and Social Policy is an esteemed academic journal published by Emerald Group Publishing Ltd that focuses on the intersection of drug habits and the evolving landscape of social policy. With an ISSN of 2752-6739 and E-ISSN of 2752-6747, this journal contributes significantly to the fields of Clinical Psychology, Health Policy, and Public Health, and is ranked in the Q3 category across multiple disciplines in the 2023 categorizations. Featuring research that spans from 2022 to 2024, the journal provides a platform for critical insights and evidence-based discussions that are essential for understanding the social implications of drug use. Despite its current quartile ranking, the journal aims to elevate discourse among researchers, professionals, and students alike, reinforcing its commitment to impactful scholarship that can inform policy and practice. The journal is based in the United Kingdom, with its operations housed at Floor 5, Northspring 21-23 Wellington Street, Leeds, W YORKSHIRE LS1 4DL, ENGLAND. As a pivotal resource in its field, Drugs Habits and Social Policy invites contributions that can shape the future of health policy and improve societal outcomes.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

JOURNAL OF DRUG ISSUES, published by SAGE PUBLICATIONS INC, serves as a pivotal platform for researchers and professionals dedicated to the multifaceted exploration of drug-related topics across various fields, including health, medicine, psychiatry, and public health. With an ISSN of 0022-0426 and an E-ISSN of 1945-1369, this esteemed journal has maintained a consistent output since its inception in 1971 and is set to continue its contributions through 2024. Reflecting its high academic standards, it has achieved a Q2 ranking in Health (Social Science) and Q3 rankings in several related categories, underscoring its relevance and influence among scholarly work. The journal is indexed in Scopus, with respectable rankings in various medical and health-related disciplines, highlighting its role as an essential resource for those invested in the vigorous discourse surrounding drug issues. Although not an open-access publication, the journal ensures that access to its extensive research findings remains available to a broad audience, solidifying its importance in advancing knowledge and informing best practices in the field.

Suchttherapie, an esteemed journal published by GEORG THIEME VERLAG KG, serves as a critical platform within the fields of Applied Psychology and Psychiatry and Mental Health. Established in 2000 and continuing through 2024, this journal is committed to advancing the understanding and treatment of addiction and related psychological issues. Although it currently stands in the Q4 Quartile ranking and is categorized as low percentile in both Scopus Ranks and impact metrics, its significance lies in its dedication to disseminating cutting-edge research and clinical findings that contribute to the evolving landscape of therapeutic practices. Published in Germany, the journal facilitates unlimited access to the vital discourse surrounding mental health and addiction treatment, making it a valuable resource for researchers, professionals, and students alike seeking to enhance their knowledge and skills in this important area of study. As the field continues to grow, Suchttherapie plays a pivotal role in bridging practice with academic rigor, ensuring that readers remain informed on the latest methodologies and insights.

Alkoholizm i Narkomania - Alcoholism and Drug Addiction is a prominent peer-reviewed journal published by the Institute of Psychiatry and Neurology, Department of Studies on Alcoholism in Warsaw, Poland. Renowned for its commitment to advancing the fields of addiction research and mental health, this journal disseminates critical findings regarding the prevention, treatment, and societal implications of alcoholism and drug addiction. Since becoming Open Access in 2017, it ensures that researchers, professionals, and students from across the globe have unrestricted access to valuable resources and emerging studies within this vital area of public health. The journal emphasizes innovative methodologies and interdisciplinary approaches, inviting contributions that explore the complex interplay of psychological, social, and biological factors influencing addiction. By fostering a collaborative and inclusive scholarly community, Alkoholizm i Narkomania aims to contribute significantly to the understanding and resolution of addiction-related challenges worldwide.

Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

SUBSTANCE USE & MISUSE, published by Taylor & Francis Inc, is an esteemed academic journal dedicated to the multifaceted study of substance use and its implications on health and society. With a notable impact factor and categorized in the Q2 quartile across multiple fields—including Health (Social Science), Medicine (Miscellaneous), Psychiatry and Mental Health, as well as Public Health—this journal serves as an essential platform for researchers, professionals, and students alike. Spanning from 1966 to 2024, it provides a rich archive of peer-reviewed articles that explore current trends, innovative research, and evidence-based practices in the management and understanding of substance use. The journal offers various access options, catering to the diverse needs of its audience and affirming its commitment to fostering scholarly discourse in the United Kingdom and beyond. By engaging with this journal, readers can enhance their understanding of the complexities surrounding substance use, making it a crucial resource for advancing knowledge and informing policy in this critical area of public health.

The Journal of Substance Use is a vital resource for researchers, professionals, and students in the fields of health and social sciences, published by Taylor & Francis Inc.. With an ISSN of 1465-9891 and E-ISSN of 1475-9942, this journal has been at the forefront of substance use research since its inception in 1996 and continues to provide a platform for the dissemination of innovative findings and critical analysis up to the year 2024. Ranking in the Q3 category for both Health (Social Science) and Medicine (Miscellaneous) in the 2023 quartiles, the journal encapsulates a broad spectrum of issues related to substance use, including addiction, intervention strategies, and policy implications. Although not an open-access journal, it remains accessible to a wide audience. With its substantial role in enhancing understanding and addressing the multi-faceted challenges of substance use, the Journal of Substance Use is essential for all stakeholders aiming to contribute to research and practice in this crucial area.

ADDICTION, published by Wiley, is a highly regarded academic journal that serves the vibrant fields of Medicine and Psychiatry and Mental Health. With an impressive impact factor reflective of its significance—ranking in the top 8% and 7.5% of its categories respectively—this journal is esteemed for its rigorous peer-reviewed research which spans a wide array of topics related to addiction, including pharmacology, prevention, and treatment modalities. Since its inception in 1993, ADDICTION has continually provided a platform for innovative research, shaping the discourse and influencing clinical practices worldwide. This journal, based in the United Kingdom at a prestigious location in Hoboken, NJ, stands as a beacon for researchers, practitioners, and students alike, committed to advancing understanding and strategies to combat addiction-related challenges. Although it is not an Open Access publication, the journal's contribution to the field remains invaluable, ensuring that cutting-edge findings are disseminated widely among professionals dedicated to improving mental health outcomes.

International Journal of Drug Policy, published by Elsevier, stands as a crucial scholarly platform dedicated to advancing the field of drug policy research. With an impactful focus on health policy and medicine, this journal holds a prestigious Q1 ranking in both Health Policy and Medicine (miscellaneous) categories as of 2023, reflecting its high-quality contributions to the discourse surrounding drug use, regulation, and public health. Spanning publication from 1998 to 2024, the journal's rich archive of research serves as an essential resource for researchers, professionals, and students alike. While the journal is not open access, it provides invaluable insights and significant findings that drive policy-making decisions and foster evidence-based practices in drug management and health interventions. With a Scopus rank of #28 out of 310 in Health Policy and #55 out of 398 in Medicine (miscellaneous), the International Journal of Drug Policy is indispensable for those committed to exploring and understanding the complexities of drug-related issues on a global scale.